AngioDynamics 2026 Q1 Earnings Beats Expectations with 16.1% EPS Improvement

AngioDynamics (ANGO) reported its fiscal 2026 Q1 earnings on Oct 02nd, 2025, delivering results that exceeded expectations. The company improved its full-year guidance for net sales, Med Tech net sales growth, Adjusted EBITDA, and Adjusted EPS, indicating strong momentum. It also expects to remain cash flow positive for the full year 2026, despite ongoing challenges.

Revenue
The total revenue of AngioDynamics rose by 12.2% to $75.71 million in 2026 Q1, surpassing the $67.49 million recorded in 2025 Q1. The Med Tech segment led the charge, growing 26.1% to $35.26 million, driven by robust performance in Auryon, AngioVac, and NanoKnife. Meanwhile, the Med Device segment saw a more modest 2.3% increase to $40.45 million, maintaining its contribution to the company's diversified revenue base.

Earnings/Net Income
AngioDynamics narrowed its losses significantly, with a loss of $0.26 per share in 2026 Q1, compared to a $0.31 per share loss in the prior-year period, representing a 16.1% improvement. The company's net loss also decreased to $-10.90 million in 2026 Q1, from $-12.80 million in 2025 Q1, showcasing progress in cost control and operational efficiency.

Price Action
The stock price of AngioDynamics fell by 7.78% on the latest trading day, but it rebounded strongly in the following week, surging 10.86% and gaining 12.24% month-to-date, reflecting investor confidence in its earnings performance and strategic direction.

Post Earnings Price Action Review
Following the earnings report, the market responded favorably, with the stock recovering from a single-day drop. While the short-term volatility indicates market evaluation, the positive weekly and monthly performances suggest that investors view the company's strong Q1 results and improved guidance as positive catalysts for future growth.

CEO Commentary
James Clemmer, CEO, underscored the company's strategic success in leveraging high-growth med tech markets and operational efficiency. He highlighted the Med Tech segment's 26.1% growth as a key driver and expressed confidence in the company's ability to sustain momentum in 2026. Clemmer emphasized Auryon’s leadership in peripheral arterial disease and the ongoing clinical studies like AMBITION BTK, which aim to expand treatment options and market reach. He also noted the promising growth in Mechanical Thrombectomy and NanoKnife, both of which are set to benefit from product innovation and market adoption.

Guidance
AngioDynamics has raised its full-year 2026 revenue guidance to $308–$313 million, projecting 5–7% growth over 2025’s $292.7 million. The Med Tech segment is expected to grow between 14–16%, while Med Device is forecasted to remain flat. The company anticipates a gross margin of 53.5–55.5%, incorporating an estimated $4–$6 million annual impact from tariffs. Adjusted EBITDA is expected to reach $6–$10 million, with adjusted loss per share forecasted at $0.33–$0.23. Cash flow is expected to be positive for the year, with Q4 being a significant contributor.

Additional News
AngioDynamics announced two significant clinical trials in the 2026 Q1 report. The AMBITION BTK trial and the RECOVER-AV clinical trial both enrolled their first patients, marking key milestones in the company’s commitment to advancing peripheral artery disease and pulmonary embolism treatment. Additionally, results from the NanoKnife PRESERVE study were published in the European Urology journal, demonstrating the system’s efficacy and quality-of-life benefits for prostate cancer patients. These developments underscore AngioDynamics' focus on expanding its clinical presence and generating evidence-based data to support broader access to its innovative medical technologies.